Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting stathmin in prostate cancer.

Sucharita J Mistry1, Alexander Bank, George F Atweh

  • 1Division of Hematology-Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. sucharita.mistry@mssm.edu

Molecular Cancer Therapeutics
|December 24, 2005
PubMed
Summary

Researchers developed adenoviral vectors targeting stathmin mRNA to inhibit prostate cancer cell growth. This approach effectively reduced stathmin expression, induced apoptosis, and halted cancer cell proliferation, offering a potential new therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stathmin 1 deficiency induces erythro-megakaryocytic defects leading to macrocytic anemia and thrombocythemia in Stathmin 1 knock out mice.

Blood cells, molecules & diseases·2020
Same author

Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.

Cancer cell·2019
Same author

Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney.

Kidney international·2016
Same author

Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis.

American journal of hematology·2015
Same author

p27(Kip1) and STMN1: partners again?

Cell cycle (Georgetown, Tex.)·2014
Same author

New paradigms in microtubule-mediated endocrine signaling in prostate cancer.

Molecular cancer therapeutics·2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Stathmin is a key microtubule-destabilizing protein overexpressed in many cancers.
  • Targeting stathmin offers a potential strategy for cancer therapy by disrupting mitosis.

Purpose of the Study:

  • To evaluate the therapeutic potential of adenoviral vectors expressing anti-stathmin ribozymes in prostate cancer.
  • To assess the impact of stathmin inhibition on cancer cell growth, cell cycle, and apoptosis.

Main Methods:

  • Development of replication-deficient bicistronic adenoviral vectors coexpressing GFP and anti-stathmin ribozymes.
  • Testing in an androgen-independent LNCaP prostate cancer model.
  • Analysis of stathmin expression, cell growth, cell cycle, clonogenic potential, and apoptosis.

Related Experiment Videos

Main Results:

  • Efficient transduction and significant inhibition of stathmin expression in LNCaP cells.
  • Dose-dependent growth inhibition and G2-M cell cycle arrest.
  • Induction of apoptosis, evidenced by caspase-3 activation and DNA fragmentation.

Conclusions:

  • Adenovirus-mediated delivery of anti-stathmin ribozymes demonstrates potent anti-cancer effects in vitro.
  • Stathmin inhibition via gene therapy is a promising strategy for prostate cancer treatment.
  • Further in vivo studies are warranted to confirm therapeutic efficacy.